Oxaliplatin Gry (Oxaliplatin)

Oxaliplatin is employed in chemotherapy regimens targeting cancers of the gastrointestinal tract.

• Colorectal cancer: enhances tumor response when combined with fluoropyrimidines and leucovorin.
• Gastric cancer: contributes to tumor shrinkage in combination protocols.
• Pancreatic cancer: used as part of multi‑drug regimens to improve disease control.
• Esophageal cancer: added to standard chemotherapy to increase response rates.
• Appendiceal cancer: incorporated in systemic therapy for advanced disease.
• Peritoneal carcinomatosis: applied in regional perfusion techniques to reduce tumor burden.

• Oxaliplatin forms reactive platinum complexes that covalently bind to DNA, creating intra‑ and interstrand cross‑links that inhibit DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells, providing its antineoplastic effect.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Diarrhea: loose stools that may require supportive care.
• Fatigue: generalized tiredness during treatment cycles.
• Myelosuppression: reduced blood cell counts, increasing infection risk.
• Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis or bronchospasm.
• Acute neurotoxicity: sudden onset of muscle cramps or spasms.
• Hemolytic anemia: destruction of red blood cells.
• Thrombotic events: blood clot formation in veins or arteries.
• Renal impairment: decreased kidney function requiring monitoring.
• Cardiotoxicity: rare heart rhythm disturbances.

When using Oxaliplatin, clinicians should observe several safety measures to minimize risks.

• Renal function: assess baseline creatinine and monitor during therapy.
• Hepatic function: evaluate liver enzymes before each cycle.
• Neuropathy monitoring: conduct regular neurological assessments.
• Hematologic monitoring: perform complete blood counts frequently.
• Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risk.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Oxaliplatin may interact with other agents, requiring careful management.

Major Interactions (Avoid)

• Nephrotoxic drugs: concurrent use can worsen kidney injury.
• Highly protein‑bound agents: may displace oxaliplatin, increasing toxicity.

Moderate Interactions (Monitor Closely)

• Anticoagulants: heightened bleeding risk, monitor coagulation parameters.
• Antiemetics: potential additive central nervous system effects.
• CYP450 modulators: may alter plasma levels of co‑administered drugs.
• Radiotherapy: combined neurotoxicity risk, especially peripheral neuropathy.
• Immunosuppressants: increased infection susceptibility, require vigilance.